| scholarly article | Q13442814 |
| P50 | author | Lena E Friberg | Q88235607 |
| P2093 | author name string | Otto Cars | |
| Elisabet I Nielsen | |||
| Ami F Mohamed | |||
| P2860 | cites work | One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates | Q24244642 |
| Clinical Pharmacokinetics of Penicillins, Cephalosporins and Aminoglycosides in the Neonate: A Review | Q30437952 | ||
| Ways to fit a PK model with some data below the quantification limit | Q30668538 | ||
| Likelihood based approaches to handling data below the quantification limit using NONMEM VI. | Q31169718 | ||
| PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. | Q33219671 | ||
| Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria | Q33976467 | ||
| Simplified dosing of gentamicin for treatment of sepsis in Bangladeshi neonates. | Q34083485 | ||
| Aminoglycoside adaptive resistance: importance for effective dosage regimens | Q34277787 | ||
| Comparison of four basic models of indirect pharmacodynamic responses | Q34392881 | ||
| Gentamicin blood levels: a guide to nephrotoxicity | Q34934750 | ||
| Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model | Q35128808 | ||
| Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model | Q35135145 | ||
| Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis | Q35297198 | ||
| Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments | Q35635652 | ||
| First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. | Q36752618 | ||
| Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development | Q36949430 | ||
| Extended-interval dosing of gentamicin for treatment of neonatal sepsis in developed and developing countries. | Q37237625 | ||
| Therapeutic drug monitoring of aminoglycosides in neonates | Q37409465 | ||
| Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization | Q38626980 | ||
| MexXY-OprM efflux pump is necessary for a adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. | Q39743310 | ||
| Experience with a once-daily aminoglycoside program administered to 2,184 adult patients | Q39779327 | ||
| Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance | Q39828366 | ||
| Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. | Q39881843 | ||
| Performance of gentamicin population kinetic parameters in Portuguese neonates | Q40234762 | ||
| Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration | Q40284216 | ||
| The frequency of persisters in Escherichia coli reflects the kinetics of awakening from dormancy | Q42738008 | ||
| Empirical treatment of neonatal sepsis: are the current guidelines adequate? | Q43440303 | ||
| Comparison of gentamicin dosing regimens using an in-vitro model. | Q43779314 | ||
| Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 | ||
| Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study. | Q45984535 | ||
| Determination of extended-interval gentamicin dosing for neonatal patients in developing countries | Q50457389 | ||
| Eight years' experience of an extended-interval dosing protocol for gentamicin in neonates. | Q51848061 | ||
| Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates. | Q51997391 | ||
| Three new residual error models for population PK/PD analyses. | Q52322170 | ||
| Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. | Q54319060 | ||
| Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve | Q71559681 | ||
| The effect of aminoglycoside-induced adaptive resistance on the antibacterial activity of other antibiotics against Pseudomonas aeruginosa in vitro | Q71876778 | ||
| Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM | Q77296898 | ||
| Application of a combined effect compartment and binding model for gastric acid inhibition of AR-HO47108: a potassium competitive acid blocker, and its active metabolite AR-HO47116 in the dog | Q79871588 | ||
| Aminoglycoside/beta-lactam combinations in clinical practice | Q81341829 | ||
| Observational trial of a 48-hour gentamicin dosing regimen derived from Monte Carlo simulations in infants born at less than 28 weeks' gestation | Q81549728 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| gentamicin | Q422482 | ||
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 179-188 | |
| P577 | publication date | 2011-10-28 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants | |
| P478 | volume | 56 |
| Q38966188 | A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants |
| Q30619387 | A model-based approach to predict longitudinal HbA1c, using early phase glucose data from type 2 diabetes mellitus patients after anti-diabetic treatment. |
| Q39665401 | A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure |
| Q51118472 | A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing. |
| Q37733479 | A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection. |
| Q46078169 | An automated sampling importance resampling procedure for estimating parameter uncertainty |
| Q36171772 | Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill |
| Q50076206 | Balancing Antibacterial Efficacy and Reduction in Renal Function to Optimise Initial Gentamicin Dosing in Paediatric Oncology Patients |
| Q47897914 | Can a pharmacokinetic/pharmacodynamic (PKPD) model be predictive across bacterial densities and strains? External evaluation of a PKPD model describing longitudinal in vitro data. |
| Q40719307 | Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance |
| Q53802828 | Conditional probability analysis of multidrug resistance in Gram-negative bacilli isolated from tertiary medical institutions in South Korea during 1999-2009. |
| Q26853629 | Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics |
| Q36352429 | Dual action antimicrobials: nitric oxide release from quaternary ammonium-functionalized silica nanoparticles |
| Q27009662 | Educational paper: do we need neonatal clinical pharmacologists? |
| Q41827371 | Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies. |
| Q51123254 | Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation. |
| Q57240383 | Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis |
| Q92127147 | Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans |
| Q40857961 | Gentamicin dosing strategy in patients with end-stage renal disease receiving haemodialysis: evaluation using a semi-mechanistic pharmacokinetic/pharmacodynamic model |
| Q46488798 | Gentamicin use in neonates: should we have a change of practice? |
| Q101327707 | Model-informed drug development for antimicrobials: Translational PK and PKPD modelling to predict an efficacious human dose for apramycin |
| Q47273948 | Modeling the emergence of antibiotic resistance in the environment: an analytical solution for the minimum selection concentration. |
| Q33827819 | Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology |
| Q38664871 | Pharmacokinetics and pharmacodynamics in antibiotic dose optimization. |
| Q38215682 | Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants. |
| Q38696468 | Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates |
| Q39071799 | Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy. |
| Q34570930 | Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates |
| Q40087805 | Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs. |
| Q41494950 | Stochastic process pharmacodynamics: dose timing in neonatal gentamicin therapy as an example |
| Q38709104 | Therapeutic drug monitoring in neonates |
| Q38853629 | Translational Pharmacometric Evaluation of Typical Antibiotic Broad-Spectrum Combination Therapies Against Staphylococcus Aureus Exploiting In Vitro Information |
| Q35168882 | Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling. |
| Q93075556 | tRNA Methylation Is a Global Determinant of Bacterial Multi-drug Resistance |
Search more.